Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010 Jan 15; 116(2):292-301.

View in: PubMed

subject areas

Adult
Aged
Breast Neoplasms
Cancer Vaccines
Epitopes
Female
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Middle Aged
Peptide Fragments
Receptor, ErbB-2
Vaccines, Subunit

authors with profiles

ELIZABETH ANN MITTENDORF